News

Indian pharmaceutical company Lupin has awarded the licensing rights of its Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1) programme to AbbVie. The deal gives AbbVie exclusive global

PNH is a rare and acquired blood disease that results in the rupture or destruction of red blood cells (hemolysis). People diagnosed with PNH lack a certain protein

The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will

CellforCure is a major French contract development and manufacturing organization engaged in the production of cell and gene therapies in Europe. As per terms of the deal, Novartis

The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were

Under the terms of the agreement, Agenus will receive $150m upon closing, which includes a $120m upfront cash payment and a $30m equity investment. The agreement also includes

The new facility, which is strategically located in close vicinity to the Ljubljana Airport, will carry out the distribution of finished products worldwide and will be used for

Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent

UPSA is a French pharmaceutical manufacturer, which develops and produces pharmaceutical drugs and supplements for everyday ailments. The company provides various products in therapeutic areas, including pain, cough